Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

Teladoc was once a high flying innovative technology name. While Teladoc remains innovative, operations have been under some recent pressure, and the stock has absolutely cratered.

Teladoc: Panic And Fear

Investors took a pundit's new, bearish take on their company to heart.

Why Teladoc Health Was a Sickly Stock Today

Shares of Teladoc Health Inc. TDOC, -6.59% were dropping more than 6% in Wednesday morning trading after Guggenheim analyst Sandy Draper downgraded the stock to sell from neutral. He wrote that Teladoc's revenue and earnings before interest, depreciation, and amortization (Ebitda) could face further pressure from various macroeconomic factors, including uncertainty that is pushing out sales cycles for Teladoc as well as inflationary constraints on consumers.

Teladoc may have to choose between 'the lesser of two evils,' analyst says in downgrade

Like other Covid-19 darlings such as DocuSign and Peloton Interactive, Teladoc saw accelerated growth, but now things are a little different.

Teladoc Health Gets Another Downgrade. This Time, an Analyst Says Sell.

Here's why investors should like -- and dislike -- this leading telehealth stock.

Teladoc Stock: Bull vs. Bear

Invitae

Fate Therapeutics

Markforged Holding Corp

Roblox

Cathie Wood's Ark Invest has performed well recently, with shares of her flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK ), up more than 15% during the past month. The performance was driven by the release of July's consumer price index (CPI) report.

The 5 Top Stocks Cathie Wood Is Buying Now

Shares of Teladoc Health Inc (NYSE: TDOC) are in focus on Friday after a DA Davidson analyst said the beaten down telemedicine company is a “buy” at current levels.

This beaten down Cathie Wood stock is a ‘buy': DA Davidson

Teladoc stock has fallen 88% since peaking last year. There are still investors that feel the time is right to buy or add to a position.

3 People That Still Believe in Teladoc

An analyst's positive new take on the company is mitigated by concerns about its recent performance.

Why Teladoc Crawled Only Marginally Higher on Thursday

Shopify

Zoom Video

Those who flocked to the stay-at-home type of stocks during the pandemic were rewarded handsomely with considerable gains. In 2022, the story has been vividly different.

Revisiting the Pandemic Winners: Time to Buy?

Shares of telehealth company Teladoc (NYSE: TDOC ) are in the spotlight, as Cathie Wood's Ark Invest has purchased shares of the company every day this week. From Aug. 8 to Aug. 10, Ark purchased 344,629 shares of TDOC stock.

Cathie Wood Is Buying Teladoc (TDOC) Stock Up in a Frenzy

It appears Cathie Wood is as long on biotech stocks as ever. The Ark Invest founder and manager has been buying up popular biotech companies like Ginkgo Bioworks (NYSE: DNA ), Invitae (NYSE: NVTA ) and Teladoc (NYSE: TDOC ) en masse this summer.

Cathie Wood Is Doubling Down on Biotech Stocks DNA, NVTA, TDOC

Fiverr

Upstart Holdings

Not even a bear market decline can faze billionaire money managers who are intent on owning innovative companies and future industry leaders.

3 Supercharged Growth Stocks Down 88% to 93% That Billionaires Can't Stop Buying

At-Home Testing Improves Diabetes Care & Control for Individuals, Providers & Payers Alike

Teladoc Health Makes A1C Testing Easier for Members with Diabetes

Cathie Wood-led Ark Investment Management bought 129,800 shares of healthcare company Teladoc Health Inc (NYSE: TDOC), valued at over $4.5 million, based on Tuesday's closing price, via four of its exchange-traded funds (ETFs).

Cathie Wood's Ark Invest Adds $4.5M In Teladoc Stock

Teladoc (TDOC) projects total visits between 4.8 million and 5 million for the third quarter.

Teladoc (TDOC) Down 10.3% Despite Q2 Earnings & Sales Beat

The stock just isn't a fit for the billionaire investor's portfolio, and it's not for the reasons you might think.

Why Teladoc Might Never Be a Warren Buffett Stock

Its recent performance leaves a lot to be desired.

Is There any Hope for Teladoc Stock in 2023?

ARK Innovation ETF

Exact Sciences

Pacific Biosciences of California

Personalis Inc

Cathie Wood's exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%.

5 Top Stocks Cathie Wood Bought This Week

NEW YORK , Aug. 5, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Teladoc Health, Inc. (NYSE: TDOC). To receive updates on the lawsuit, fill out the form:  https://claimyourloss.com/securities/teladoc-health-inc-loss-submission-form/?id=30553&from=4 The lawsuit seeks to recover losses for shareholders who purchased Teladoc between October 28, 2021 and April 27, 2022.

TDOC SHAREHOLDER ALERT: Jakubowitz Law Reminds Teladoc Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Don't let recent results scare you off what's still a solid, long-term investment.

Why Selling Teladoc Right Now Could Be a Huge Mistake

Somebody call the doctor -- this stock has fallen ill.

Can This Beaten-Down Stock Make a Comeback?

New York, New York--(Newsfile Corp. - August 4, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC) and certain of its officers.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teladoc Health, Inc. of Class Action Lawsuit and Upcoming Deadline - TDOC

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) securities between October 28, 2021 and April 27, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On April 27, 2022, Teladoc released its first quarter 2022 f

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Teladoc Health, Inc. (TDOC)

Roku

There are always bargains to be had if you just know where to look.

News for Teladoc Stock (TDOC)